Geron GERN Noncurrent liability related to sale of future royalties
Noncurrent liability related to sale of future royalties at other companies
Other financials
Where this comes from
Reported directly by Geron in its filing.
Tagged under the XBRL concept gern:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent.
The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Geron's noncurrent liability related to sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Geron's noncurrent liability related to sale of future royalties?
- Geron (GERN) reported noncurrent liability related to sale of future royalties of $110.38M in Q1 2026.
- How has Geron's noncurrent liability related to sale of future royalties changed year-over-year?
- Geron's noncurrent liability related to sale of future royalties increased by 0.0% year-over-year, from $110.38M to $110.38M.
- What does noncurrent liability related to sale of future royalties mean?
- This represents the long-term portion of debt-like obligations created by selling rights to future royalty payments to third-party investors. It serves as a non-dilutive financing mechanism for clinical-stage companies to secure capital for drug development. The balance decreases as royalty payments are made to the investors over the life of the agreement.